EAC 2016 - Update in Allergy, Asthma and Immunology

Palm Beach, FL US
June 2, 2016 to June 5, 2016

Target Audience

Practicing allergists, fellows in allergy training programs, primary care physicians who care for allergy patients and allied health professionals in the field of allergy.

Learning Objectives

Upon completion of this activity, participants should be able to:    

  • Develop optimal treatment strategies for moderate to severe allergic rhinitis
  • Utilize biomarkers and too predict therapeutic response in severe asthma and COPD
  • Prescribe optimal therapy in patients with asthma and COPD
  • Diagnose and manage eosinophilic esophagitis
  • Describe the pathogenesis of chronic urticaria
  • Diagnose and manage hereditary angioedema
  • Discuss current and future allergy immunotherapy treatment options for allergic rhinoconjunctivitis
  • Diagnose and manage allergic skin diseases including chronic urticaria, atopic dermatitis and contact dermatitis
  • Diagnose and manage drug allergy
  • Differentiate anaphylaxis from mast cell disorders
  • Evaluate and treat appropriate patients for potential immunodeficiency
Additional information
Disclosure: 

Disclosure Policy and Disclosures

As required by the Accreditation Council for Continuing Medical Education (ACCME) and in accordance with the American College of Allergy, Asthma and Immunology (ACAAI) policy, all educational planners, presenters, instructors, moderators, authors, reviewers, and other individuals in a position to control or influence the content of an activity must disclose all relevant financial relationships with any commercial interest that have occurred within the past 12 months. All identified conflicts of interest must be resolved and the educational content thoroughly vetted for fair balance, scientific objectivity, and appropriateness of patient care recommendations. It is required that disclosure be provided to the learners prior to the start of the activity. Individuals with no relevant financial relationships must also inform the learners that no relevant financial relationships exist. Learners must also be informed when off-label, experimental/investigational uses of drugs or devices are discussed in an educational activity or included in related materials. Disclosure in no way implies that the information presented is biased or of lesser quality. It is incumbent upon course participants to be aware of these factors in interpreting the program contents and evaluating recommendations. Moreover, expressed views do not necessarily reflect the opinions of the ACAAI.

All identified conflicts of interest have been resolved.

 Cem Akin, MD – Speaker

 Novartis, Patara Pharma, Blueprint Medicines, Deciphera – Consultant

 Aleena Banerji, MD – Speaker

 Shire, Dyax, Alnylam Pharmaceuticals, CSL Behring, Biocryst – Consultant

 Shire, Dyax, Biocryst – Research Grant

Christopher Brightling, MD – Speaker

GlaxoSmithKline, AZ/MedImmune, Roche/Genentech, Chiesi, Novartis, Theravance, Pfizer, Boehringer Ingelheim – Consultant

GlaxoSmithKline, AZ/MedImmune, Roche/Genentech, Chiesi, Novartis, Boehringer Ingelheim – Research Grant

Don Bukstein, MD – Speaker

AstraZeneca, Merck, Novartis, Circassia, Genentech, Meda, Teva – Speaker/Honorarium

Tom Casale, MD – Speaker

Merck, Stallergenes, Circassia, Genentech, Novartis – Consultant/Research Grant

Ray Davis, MD – Speaker

Teva, Merck, Meda, Mylan, AstraZeneca, Sunovion/Neohealth, Baxalta, Alcon, Onyx – Consultant

Teva, Merck, Meda, Mylan, AstraZeneca, Alcon – Speaker/Honorarium

Aaron Drucker, MD – Speaker

Regeneron/Sanofi – Investigator

Michael Foggs, MD – Speaker

AstraZeneca, Boehringer Ingelheim, Boston Scientific, Meda, Merck, Mylan, Teva – Consultant/Honorarium

Boehringer Ingelheim, Meda – Speaker

Luz Fonacier, MD – Speaker

Church and Dwight Co. – Consultant

Genentech, Merck – Research Grant

Baxter – Speaker

Aidan Long, MD – Speaker

Genentech, Novartis – Advisory Board

Harold Nelson, MD – Speaker

Merck, Circassia – Consultant

Merck, Circassia, *AstraZeneca, *Pearl Therapeutics – Honorarium *DSMB

Circassia – Research Grant

Elena Perez, MD – Speaker

Baxalta, CSL Behring, Grifols – Consultant

Robert Settipane, MD – Planner/Moderator

Merck, Genentech, Mylan, Novartis, Circassia, Oriel Therapeutics – Research Grant

OceanSide Publications – Stockholder

Russell Settipane, MD – Planner/Moderator/Speaker/Reviewer

AstraZeneca, Teva, Merck – Consultant

AstraZeneca, Teva, Merck, Genentech, Mylan, Meda, Greer/Stallergenes – Speaker

Merck, Genentech, Mylan, Meda, Novartis, Circassia, Oriel Therapeutics – Research Grant

OceanSide Publications – Employee/Stockholder

Ellen Sher, MD – Speaker

Meda, Teva, Sanofi, Baxalta – Consultant

Meda, Teva, Alcon, Greer/Stallergenes, Merck, Boehringer Ingelheim – Speaker

Meda, Teva – Honorarium

Teva, Greer/Stallergenes, Merck, Circassia, Genentech, OptiNose US, Sanofi, Allergy Therapeutics, AstraZeneca, Biota, Afferent, Mylan, Amgen, Biota – Research Grant

Jonathan Silverberg, MD – Speaker

Abbvie, Anacor, MedImmune, Regeneron – Consultant

Regeneron – Speaker

Julie Wang, MD – Speaker

Aimmune – Consultant

JDP Therapeutics – Stock Options

The following have no relevant financial relationships to disclose:

Joseph Bellanti, MD – Planner/Moderator

William Greisner, III, MD – Planner/Moderator

Ginny Loiselle – Staff

Michael Slaughter, MD – Planner/Moderator

Course summary
Available credit: 
  • 15.00 AMA PRA Category 1 Credit™
  • 15.00 Attendance
Course opens: 
06/02/2016
Course expires: 
06/05/2018
Event starts: 
06/02/2016 - 4:15pm
Event ends: 
06/05/2016 - 10:00am
Cost:
$0.00
Rating: 
0
The Breakers
O1 S. County Road
Palm Beach, FL 33480
United States

Available Credit

  • 15.00 AMA PRA Category 1 Credit™
  • 15.00 Attendance

Accreditation Period

Course opens: 
06/02/2016
Course expires: 
06/05/2018

Price

Cost:
$0.00
Please login or create an account to take this course.